you, quarter update Mark, the the AutoLap our conference Thank will after provide open operating welcome today's financial second to overview, discuss call. for line announced and call, Joe which, on we'll I'll XXXX recently our performance. then quarter a an up to provide and our I to over turn second On questions. transaction call
second as And instruments, disappointed predict, difficult quarter we results capital of and recognition made was that are working our quarter in having guidance. in below $X.X during with and as pipeline. was region. developing Taiwan deferred performance. the in particularly, sale revenue come of reported the hospital million service stated with We're We system well our inherently EMEA to system end-user when commercial surgery with comprised revenue sites began. Starting sale as prior those one The of from accessories sales until system a to our the an before, sales
half to improved of drive in continue in year. foundation putting performance We that to feel solid a place we're the back the
results provide confidence. consistent that and regain stronger However, commercial to more to need we we understand investor
to MST to leverage the adjusted business and image that bolster technological performance. I of a key to will the In I'd how like of areas improved drive overview we've In strategy XX. intent of our XXXX, of AutoLap with to acquired October IP capability divestiture the analytics Senhance. that we announced surgical on their July we provide and just number a moment, review an our technology
laparoscopic addition portfolio, a system very an IP in AutoLap, image-based scope to traditional called a positioning which used is had In launched commercially procedures. MST product strong
so the on as transaction, the July When could acquisition, product AutoLap announced to remain other were we be we tooling that we of we the that commercializing the stated the investing Senhance. we In product would sale focused inventory, AutoLap and XXXX, stand-alone physical a MST assets not IP entire sale this incorporate selling retained in assets. company into software has acquired from and same our GBIL, relevant MST to no so the SurgiBot talent Senhance. the that impact legacy know-how asset all team, the We and on acquired IP, plans the
this to be on million good later company The progress to are the on in expand We in the to call. continue cash. paid front, which I'll proceeds make total $XX
an equity is company, details additional into of more will Joe In addition, which shortly. investment the on million $XX making GBIL provide
to key making to the to time would I I some drive our this forward. to are initial and begin some of move sharing our now market adoption progress, we commercialization with U.S. like our efforts Senhance global approach commercial our learnings like starting in spend changes in in discussing of the by U.S. laparoscopy with we the from would the digital as
development initial more heavily on less activities. was focused sales with geographies, approach resources a on of in focus targeted our broader and First, activities market
of did ramp sites performed specialties. make initial volumes spectrum quickly early did across routinely not a surgery broad case we some While or these sales,
As a and and speakers allow establish efforts proctors. we did our of bolster grow advocacy to surgeon surgeon foundation to a sales not base result, our
base, to have now installed drive procedures. are have a utilization performing that we existing clinical sites We within our resources consistently across added of surgery and variety
a system. and convert are into and public of actively resources Senhance network to purchased market proctors potential number a craft of their a this story speakers. marketing patients. have And with them added to to stronger envision successfully help We we us help We to begun also hospitals who and economic the programs to using have clinical surgeons worked
and marketing are plans. analysis C value-based the health hospital We now engaging arguments, with care thoughtful routinely Suite economic
expectations. have is prospects U.S. system early competitor, use. clinical System impacted delight the consistently customers, robotics Early with which not well-established experience did the Secondly, market and potential and mature Senhance so evaluations high customers
and experiences these quickly impacted early While to activities feedback. pipeline negatively our them, satisfaction we resolve customer worked
initial launch configuration energy laparoscopy. is the in device, commonly which advanced instrument used addition, also an lacked In a
leveraged the such our and and monitor feedback most eye-tracking experience have with to as significantly software advance of and earlier improvements system, XD visual better experience available. a best-in-class XK We make customer to introduction a the the hardware
growing now pay STORZ a compatibility resulted experience, off system We've Senhance higher the which has promise launched also surgeon consistent Stryker, the clinical delivering video to in and surgeon. within of open as attractiveness installed changes our have We base. leading of the our which more architecture led laparoscopic imaging have use with we products energy also system, have quality, Novadaq, from continued These to ConMed. ultrasonic a increased of to us substantially
Lastly, in our selling the early had commercial experienced market. approach was hire salespeople robotics to that
with result, were primarily and open relationships a strongest performing As their procedures. urologist surgeons
salespeople support. that as surgeon robotic to build focus sales. enthusiastic allowed in clinical of on Given opposed digital with to a opportunities laparoscopy, us laparoscopy hiring funnel focus initially our with is a began on strong we and relationships surgeon large U.S. pivoted capital This
emerging believe to capital includes our mature more diversity making team However, convert includes a We is that the even positioned and process, system our robotics had navigating robotic sales. success of selling limited experience surgeon laparoscopic, sales if companies. best challenging that for more team interest into experience it it
sales have a leadership wealth recently robotics sales We of of and our hiring capital our bolstered who experience Sales, additional emerging talent talent. that and has President by with supplemented Vice with a technologies, team
began Surgical experience, and robotics and an of in capital now routinely substantial per with including March, of is month the performing recent bring hires One Belt new Blue success our Meridian that frequently These robotics years Health performing early surgery surgical Senhance over launch, in commercial Medrobotics. Hackensack XX Mako is approach example Pascack and intuitive Valley, a their exceeds new number. at which procedures
and his a volume campaign proctor Amit part launched Valley become drive described experience their his the to experience optimism to multiple about opportunities also with setting. market. in hospital in story feature Senhance. the local role for that in Senhance's grow has public-speaking cover and to our Pascack Outpatient adoption recent has a his to the Senhance and as in has a use and radio Trivedi in system its was strategy print He of Dr. of share regional participated periodical Surgery featured positive
in pipeline close We U.S. feel to momentum have the now we that deals.
some As maximize blocks U.S. market as will probable more these time we've but When deep meaningfully take to can increase footprint always sales pipeline capitalize we building to before on yield are a still our established, describe early it's this mentioned is sufficiently growth. ability to drive substantial our the we to opportunity. developed before, feel had process, we it'll and that It in the revenue. now
becoming a to This sale the sale community. expand system Rhine-Westphalia. the a our comprehensive market sale facilities, extensive result us a breadth Transitioning have direct inpatient Senhance in base German This the of the EMEA. The surgeon hospital base the North a Western both elevated netted Hospital is The XXX-bed considerable the system quarter in region Evangelical recognition was Senhance EMEA Senhance a customer in and terms is further geographic to medical The and outpatient advocacy successfully the brand. surgery. of they already in of begun with sold second hospital. is is of using in efforts to and in development. direct name installed and in U.S. Europe. was Bielefeld familiar to And has advanced LAPRES
EMEA do region system out. ebbs in first This of used performance in half week week believe We surgery, routinely the and of flows multiple to accounts and more with sales has where the the the process. capital is has region the
For environment in surgeries in a has Medical XXXX. of system Netherlands late in multi-specialty performed of example, beginning over Center XXX the since the use Máxima
countries well have but hospitals at distributors Western small Each advance frequent able benefit EMEA there us in the now team that efforts. of several countries. spans of Our country developing that Many Europe have supported more one is many to own are customers these Senhance into pace, advocacy are as other help use. direct by are in our where its we integrated or region sales a as
Turning to Asia.
utilization Taiwan We significant up three progress in active continue system. quickly advocates sites ramping with the to of make surgeon that their are having
months using Jen two XX Veterans Fu Hospital the and the Hospital system. first in General first three installations, completed University have over Our surgeries Taipei Catholic
The in started their clinical progress. program late-July and making is third account good
quarter, have the third hospital, and in region, the the in from another received to this install sale plan fourth the we we system order a Taiwanese representing quarter. purchase In third
Turning to Japan.
in the we we and approval regulatory previously through for we've and obtained of this focused longer have short regulatory device of on the takes the tremendous established XX broad progress as market. reimbursement We're we typically team, to than amount very In use this in a proud announced, received very have what ushering far Senhance. than As were months, of reimbursement less made process able time focused we accomplishment achieve. that medical a Japan
the are wide across recent for to range equivalent We surgeries and reimbursement is specialties. decision, procedures Senhance that and by general, in of patients and across result of traditional This to which procedures rates thrilled Japan bariatric colorectal, a gynecologic, of a for laparoscopic laparoscopy. as fantastic it XX applies a reimbursement urologic variety malignant high-volume and benign covers
world, second a technologies. the well in interest for Japanese it's new of level several the the market demonstrates markets extremely surgical sets the robotics largest reasons: Senhance up reminder, As in First, for which
third, XX% government world cost-sensitive of health leading to in with representing in funding approximately is cost, it among in for it is the the terms environment. world Second, And of laparoscopic leader all highest care extremely surgeries. adoption the an laparoscopy
strategy position the laparoscopic our best-in-class procedure reasons, digital focus space. instrument cost and with us well these success For in for the per robotic reusable
appoint the had deferring in we distributor Japan. In call, Japan our announced in decision appoint reassess coverage, Considering our to near opportunity overall in planning future. robust addressable strong, and we last a to the long-term market given the a the while were we reimbursement strategy, distributor we reevaluate that total the are go-to-market
of of quarter milestone significant and shift front, instrumentation our and Ultrasonic our gears the products that me first installations are development let and used to all allows cost U.S. extremely the with System. note, surgeries. least Senhance we the Of to of On Senhance product estimate this procedure achieved now that increase hospital. replaces the at Now, product product adding be per We in the time, use approval FDA in XX% standard this revenue in perform will laparoscopic over so a to this in EMEA. These us without instrument, efforts. virtually our well a of in
articulating X-millimeter instruments on the in bringing Senhance working through been also the We've U.S.
on Mark based EMEA. this instruments in our commercial some articulated countries time, XX-millimeter had to CE product has with success the completely have a for we different reminder, a As contributed and accept available Senhance that design the in
year received Mark surgeon evaluations We application best undertook CE the devices. to the quarter instruments in clinical these the last feedback fourth X-millimeter Europe and of for gain on in of
filed for the this later with clearance XXXX in December a also products We clearance FDA of expectation these year. of
When us routinely plan one usability we the consuming request time $X FDA, and received execute cost over feedback are study. their and These for to conduct. of to from a perform can to was million studies
some While conduct the these implementing to we to further this limited EMEA were launch increase opportunities utility the highlighted plans our instruments. testing, of in
current frame the We these have the incorporate application. to required determined within changes that we time maintain cannot by the FDA
launch cases these resubmit limited our will we best-use with the from application for when withdraw and those tools define EMEA activities such, these are FDA the As focus the better products, completed. the FDA, new current of on
work study, to usability to us other for initiatives. not that projects usability can study the we single study addition usability increase to multiple dramatically spread so across cost, align allowing a investment also The more multiple initiatives. may does will products a study the leverage that our require We X of
we call, the exploring shared last approach to our for the indication on our briefly Also pediatric Senhance.
adoption larger technologies a but Because devices robotics is be existing population. adult and instrument this forced surgeons for limited typically population. instruments have of designed utilize anatomy, working solution, control so on seem the natural As to in when visualization smaller reminder, would important and pediatric to a the larger instruments are
CE quarter Based followed -- CE in our year, in Since a robotic this this to position for make believe instruments, we approval this on first-ever continued may update, robotic year. have progress we Mark be control, We address we fourth unique next the instrument by anticipate Mark feedback haptic on X-millimeter in Senhance's the to obtaining submitting front. market. of last
Senhance the in to how indications. FDA the to opportunity determine leverage to inform us then expand position approach to to across clinical gain as will We these around expect other markets Senhance we Mark over and Ultimately, the CE best to experience this world. learnings timing
with testing integration regarding progress technology, submission make made MST's continue solid of surgical the analytics to FDA and application. product by we And of the followed ongoing XXX(k) image an development
new and installed shared to future capabilities We well expect end pipeline the filing of as continue as to our of energized the complete has XXXX, interest in around the our these base accounts. the
to the to I over call Joe turn would a provide like now to financial review.
